Shares of Vertex Pharmaceuticals, Inc. were in the spotlight in premarket trading Tuesday as the biotech company received ...

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach ...

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue ...

In Vertex's most recent quarter, the company grew revenue at an 18% y/y pace to $170.4 million. This isn't bad: but we note that several points of Vertex's growth are stemming from recent ...

Vertex Pharmaceuticals stock declined almost 13% in six months due to poor test results for a new drug. When it comes to the drug and biotech sector, a major pipeline setback can hit the stock ...

Vertex Pharmaceuticals beat expectations for revenue but missed on earnings. The company has two recent FDA approvals and several treatments in late-stage trials. The core CF treatments make up ...